Saturday, June 20, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 444 of 1,261
  1. US 10550386

    Monomers and oligonucleotides comprising cycloaddition adduct(s)

    Alnylam Pharmaceuticals, Inc. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  2. US 10548879

    (2R,4R)-5-(5′-chloro-2′-fluorobiphenyl-4-yl)-2-hydroxy-4-[(5-methyloxazole-2-carbonyl)amino]pentanoic acid

    Theravance Biopharma R&D IP, LLC · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  3. US 10548970

    Human rotavirus G9P[6] strain and use as a vaccine

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  4. US 10548302

    Fibrillin-1 mutations for modeling neonatal progeroid syndrome with congenital lipodystrophy

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  5. US 10548964

    Antigens and vaccines directed against human enteroviruses

    SENTINEXT THERAPEUTICS Sdn Bhd · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  6. US 10548883

    Benzotriazole-derived α and β-unsaturated amide compound used as TGF-β RI inhibitor

    Medshine Discovery Inc. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  7. US 10550407

    Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription

    The Regents of the University of California · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  8. US 10548890

    Parenteral formulations of lipophilic pharmaceutical agents and methods for preparing and using the same

    Platform Brightworks Two, Ltd. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  9. US 10550156

    Ang (1-7) derivative oligopeptides and methods for using and producing the same

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  10. US 10553318

    Individual and cohort pharmacological phenotype prediction platform

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  11. US 10548860

    HIF-1 modulator paint formulation and uses thereof

    United States Government as represented by the Department of Veterans Affairs · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  12. US 10548987

    Antibody-drug conjugates for targeting CD56-positive tumors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  13. US 10548971

    MERS-CoV vaccine

    Inovio Pharmaceuticals, Inc. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  14. US 10550390

    Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  15. US 10550391

    Organic compositions to treat beta-ENaC-related diseases

    Arrowhead Pharmaceuticals, Inc. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  16. US 10550195

    Tumor selective macropinocytosis-dependent rapidly internalizing antibodies

    The Regents of the University of California · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  17. US 10550193

    Methods and antibody compositions for tumor treatment

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  18. US 10550192

    Antigen-binding proteins that antagonize leptin receptor

    REGENERON PHARMACEUTICALS, INC. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  19. US 10550157

    Compositions and methods for treating central nervous system (CNS) disorders and mood disorders

    Arizona Board of Regents on Behalf of the University of Arizona · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  20. US 10550163

    Peptide fragments of netrin-1 and compositions and methods thereof

    The Regents of the University of California · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  21. US 10550085

    Deuterated compounds and uses thereof

    Aldeyra Therapeutics, Inc. · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  22. US 10548984

    RVG Derived peptides

    UNITED ARAB EMIRATES UNIVERSITY · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  23. US 10550118

    JAK inhibitors containing a 4-membered heterocyclic amide

    Theravance Biopharma R&D IP, LLC · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted
  24. US 10548979

    Light-activated compositions and methods using the same

    The Regents of the University of Colorado, a Body Corporate · Granted Feb 4, 2020 · Expires Jan 30, 2040

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.